Study on B Cells in Multiple Myeloma and Rituximab Treatment
Author Information
Author(s): Linda M. Pilarski, Eva Baigorri, Michael J. Mant, Patrick M. Pilarski, Penelope Adamson, Heddy Zola, Andrew R. Belch
Primary Institution: University of Alberta and Cross Cancer Institute
Hypothesis
The study aims to identify B cell compartments in multiple myeloma and evaluate the impact of rituximab therapy on these cells.
Conclusion
Rituximab therapy fails to deplete circulating CD20+ B cell subsets and plasma cells in multiple myeloma patients.
Supporting Evidence
- All three types of circulating B lineage cells persist despite treatment with rituximab.
- CD20+ B cells that may have bound rituximab remain detectable by their expression of CD19.
- Both identified subsets of clonotypic MM B cells express CD19 as well as expressing CD20 at moderate or high intensity.
Takeaway
The study found that certain B cells in multiple myeloma patients do not go away even after treatment with rituximab, which is supposed to target them.
Methodology
The study analyzed blood samples from 118 multiple myeloma patients, evaluating B cell subsets before, during, and after rituximab treatment over a 5-month period.
Limitations
The study did not confirm the clonotypic signature in some cases, and the flow cytometric methods used were not quantitative.
Participant Demographics
Patients with multiple myeloma, including those treated with rituximab.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Want to read the original?
Access the complete publication on the publisher's website